

## Special Issue

# Tumor Vaccines: Current Processes, Prevailing Challenges and Future Perspectives

### Message from the Guest Editors

In recent years, immunotherapy has gained significant momentum in the field of cancer treatment. Tumor vaccines are a favorable approach to cancer immunotherapy and include mRNA vaccines, DNA vaccines, and others. Eventually, vaccination may become the first truly personalized treatment for cancer. mRNA vaccines have become a promising platform for cancer immunotherapy as SARS-CoV-2 vaccines based on mRNA platforms have been rigorously evaluated and approved for widespread use. To conclude, there are a variety of problems to address in the area of tumor vaccines. This Special Issue aims to discuss the latest processes, prevailing challenges, and future perspectives related to the development of tumor vaccines. In this Special Issue, original research articles, case reports, and reviews are welcome. Research areas may include (but are not limited to) the following: basic research and clinical trials on tumor vaccines, the nature of tumor vaccines, vaccine adjuvants, and delivery strategies. We look forward to receiving your contributions.

---

### Guest Editors

Dr. Xingxing He

Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China

Prof. Dr. Honglin Jin

College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, China

---

### Deadline for manuscript submissions

1 May 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/172259](https://mdpi.com/si/172259)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).